[go: up one dir, main page]

DE69924385D1 - Verwendung von angiotensin zur behandlung von krebsmetastasierung - Google Patents

Verwendung von angiotensin zur behandlung von krebsmetastasierung

Info

Publication number
DE69924385D1
DE69924385D1 DE69924385T DE69924385T DE69924385D1 DE 69924385 D1 DE69924385 D1 DE 69924385D1 DE 69924385 T DE69924385 T DE 69924385T DE 69924385 T DE69924385 T DE 69924385T DE 69924385 D1 DE69924385 D1 DE 69924385D1
Authority
DE
Germany
Prior art keywords
angiotensin
treatment
cancer metastasis
cancer
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924385T
Other languages
English (en)
Other versions
DE69924385T2 (de
Inventor
Gavin Paul Vinson
John Richard Puddefoot
Miles Gordon Berry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818023.5A external-priority patent/GB9818023D0/en
Priority claimed from GBGB9820000.9A external-priority patent/GB9820000D0/en
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Publication of DE69924385D1 publication Critical patent/DE69924385D1/de
Application granted granted Critical
Publication of DE69924385T2 publication Critical patent/DE69924385T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/085Angiotensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69924385T 1998-08-18 1999-08-18 Verwendung von angiotensin zur behandlung von krebsmetastasierung Expired - Lifetime DE69924385T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9818023 1998-08-18
GBGB9818023.5A GB9818023D0 (en) 1998-08-18 1998-08-18 Cancer treatment
GB9820000 1998-09-14
GBGB9820000.9A GB9820000D0 (en) 1998-09-14 1998-09-14 Cancer treatment
PCT/GB1999/002727 WO2000010590A2 (en) 1998-08-18 1999-08-18 Cancer treatment

Publications (2)

Publication Number Publication Date
DE69924385D1 true DE69924385D1 (de) 2005-04-28
DE69924385T2 DE69924385T2 (de) 2006-01-19

Family

ID=26314231

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924385T Expired - Lifetime DE69924385T2 (de) 1998-08-18 1999-08-18 Verwendung von angiotensin zur behandlung von krebsmetastasierung

Country Status (7)

Country Link
US (1) US6852316B2 (de)
EP (1) EP1104305B1 (de)
AT (1) ATE291434T1 (de)
AU (1) AU5434899A (de)
DE (1) DE69924385T2 (de)
ES (1) ES2239454T3 (de)
WO (1) WO2000010590A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236761B2 (en) * 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
US20090042296A1 (en) * 2007-03-16 2009-02-12 Marie Callahan Transfection ready eukaryotic cells
US8378100B2 (en) * 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034627A2 (en) * 1996-03-19 1997-09-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. Protection of hemopoietic cells during chemotherapy or radiotherapy

Also Published As

Publication number Publication date
ES2239454T3 (es) 2005-09-16
WO2000010590A2 (en) 2000-03-02
US6852316B2 (en) 2005-02-08
AU5434899A (en) 2000-03-14
EP1104305B1 (de) 2005-03-23
ATE291434T1 (de) 2005-04-15
DE69924385T2 (de) 2006-01-19
US20020119142A1 (en) 2002-08-29
EP1104305A2 (de) 2001-06-06
WO2000010590A3 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
ATE321551T1 (de) Methoden zur behandlung des kryptorchysmus
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition